Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,041 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach.
Villalvazo P, Marzal-Alfaro B, García-Alfonso P, Revuelta-Herrero JL, Thomas F, López-Tarruella S, García-González X, Calvo A, Yakoubi M, Salvador-Martín S, López-López F, Aguilar I, Sanjurjo-Sáez M, Martín M, López-Fernández LA. Villalvazo P, et al. Among authors: thomas f. J Pers Med. 2021 Aug 13;11(8):792. doi: 10.3390/jpm11080792. J Pers Med. 2021. PMID: 34442436 Free PMC article.
Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene.
García-González X, López-Tarruella S, García MI, González-Haba E, Blanco C, Salvador-Martin S, Jerez Y, Thomas F, Jarama M, Sáez MS, Martín M, López-Fernández LA. García-González X, et al. Among authors: thomas f. Cancer Manag Res. 2018 Oct 11;10:4517-4522. doi: 10.2147/CMAR.S174470. eCollection 2018. Cancer Manag Res. 2018. PMID: 30349384 Free PMC article.
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
García-González X, Kaczmarczyk B, Abarca-Zabalía J, Thomas F, García-Alfonso P, Robles L, Pachón V, Vaz Á, Salvador-Martín S, Sanjurjo-Sáez M, López-Fernández LA. García-González X, et al. Among authors: thomas f. Cancer Chemother Pharmacol. 2020 Jul;86(1):45-54. doi: 10.1007/s00280-020-04093-1. Epub 2020 Jun 11. Cancer Chemother Pharmacol. 2020. PMID: 32529295
Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.
Loison G, Bouges Le Royer H, Marsili S, Brice A, Vintejoux J, Yakoubi M, Sirgue H, Chatelut E, Etienne-Grimaldi MC, Thomas F; on behalf of the GPCO-UNICANCER group. Loison G, et al. Among authors: thomas f. Clin Chem Lab Med. 2024 Jan 11. doi: 10.1515/cclm-2023-1096. Online ahead of print. Clin Chem Lab Med. 2024. PMID: 38198224 No abstract available.
New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G. Etienne-Grimaldi MC, et al. Among authors: thomas f. PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017. PLoS One. 2017. PMID: 28481884 Free PMC article.
Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines.
Maillard M, Eche-Gass A, Ung M, Brice A, Marsili S, Montastruc M, Puisset F, Thomas F. Maillard M, et al. Among authors: thomas f. Cancer Chemother Pharmacol. 2021 Apr;87(4):579-583. doi: 10.1007/s00280-021-04233-1. Epub 2021 Feb 15. Cancer Chemother Pharmacol. 2021. PMID: 33587160
2,041 results